Skip to content
10-K

Annual Report

Quince Therapeutics, Inc. QNCX

0001193125-26-151364

← back to feed
Filed
Apr 10, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Apr 9, 2026 163.01M sh
Shares Diluted FY 2025 · Dec 31, 2025 50.1M sh
Shares Diluted FY 2025 · Dec 31, 2024 43.26M sh
Capex FY 2025 · Dec 31, 2025 $352K
Capex FY 2025 · Dec 31, 2024 $257K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$41.43M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$31.9M
Long Term Debt FY 2025 · Dec 31, 2025 $0
Long Term Debt FY 2025 · Dec 31, 2024 $14.32M
Short Term Debt FY 2025 · Dec 31, 2025 $18.03M
Short Term Debt FY 2025 · Dec 31, 2024 $0
Cash And Equivalents FY 2025 · Dec 31, 2025 $5.81M
Cash And Equivalents FY 2025 · Dec 31, 2024 $6.21M
Stockholders Equity FY 2025 · Dec 31, 2025 −$35.71M
Stockholders Equity FY 2025 · Dec 31, 2024 $30.15M
Stockholders Equity FY 2025 · Dec 31, 2023 $85.08M
Current Liabilities FY 2025 · Dec 31, 2025 $43.23M
Current Liabilities FY 2025 · Dec 31, 2024 $7.28M
Total Liabilities FY 2025 · Dec 31, 2025 $129.24M
Total Liabilities FY 2025 · Dec 31, 2024 $84.33M
Current Assets FY 2025 · Dec 31, 2025 $22.9M
Current Assets FY 2025 · Dec 31, 2024 $44.04M
Total Assets FY 2025 · Dec 31, 2025 $93.52M
Total Assets FY 2025 · Dec 31, 2024 $114.48M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.68
Eps Diluted FY 2025 · Dec 31, 2024 −$1.31
Eps Basic FY 2025 · Dec 31, 2025 −$1.68
Eps Basic FY 2025 · Dec 31, 2024 −$1.31
Sga Expense FY 2025 · Dec 31, 2025 $15.05M
Sga Expense FY 2025 · Dec 31, 2024 $17.58M
Rd Expense FY 2025 · Dec 31, 2025 $35.38M
Rd Expense FY 2025 · Dec 31, 2024 $18.59M
Net Income FY 2025 · Dec 31, 2025 −$83.98M
Net Income FY 2025 · Dec 31, 2024 −$56.83M
Operating Income FY 2025 · Dec 31, 2025 −$58.07M
Operating Income FY 2025 · Dec 31, 2024 −$57.29M